A step closer to the use of [¹⁷⁷Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer

Lancet Oncol. 2024 Oct;25(10):1246-1247. doi: 10.1016/S1470-2045(24)00506-0.

Authors

Angela Y Jia¹, Daniel E Spratt²

Affiliations

¹ Department of Radiation Oncology, UH Seidman Cancer Center and Case Western Reserve University, Cleveland, OH 44106, USA.
² Department of Radiation Oncology, UH Seidman Cancer Center and Case Western Reserve University, Cleveland, OH 44106, USA. Electronic address: [email protected].

PMID: 39362242
DOI: 10.1016/S1470-2045(24)00506-0

No abstract available

MeSH terms

Dipeptides* / therapeutic use
Heterocyclic Compounds, 1-Ring* / therapeutic use
Humans
Lutetium* / therapeutic use
Male
Neoplasm Metastasis
Prostate-Specific Antigen / blood
Prostatic Neoplasms* / pathology
Prostatic Neoplasms* / radiotherapy
Prostatic Neoplasms, Castration-Resistant / drug therapy
Prostatic Neoplasms, Castration-Resistant / pathology
Prostatic Neoplasms, Castration-Resistant / radiotherapy
Radioisotopes / therapeutic use
Radiopharmaceuticals / therapeutic use
Treatment Outcome

Substances

Lutetium
Dipeptides
Heterocyclic Compounds, 1-Ring
Radiopharmaceuticals
Prostate-Specific Antigen
Pluvicto
Radioisotopes